Halozyme Therapeutics, Inc. reported preliminary financial estimates for 2025, expecting revenues between $1.385 billion and $1.400 billion, with royalties of $865 million to $870 million and product sales from $372 million to $377 million, on January 28, 2026. This filing details results that are subject to finalization and should not be relied upon as definitive.